Clinical bottom line
Mindfulness-based interventions (MBIs) show promise as adjunctive therapies for reducing anxiety and depression symptoms in patients with neurological disorders. Evidence from randomized controlled trials and systematic reviews suggests MBIs can improve psychological well-being and related outcomes such as sleep quality. However, effect sizes vary and methodological heterogeneity limits definitive conclusions. MBIs may be particularly beneficial when integrated into comprehensive, multidisciplinary care for neurological populations experiencing emotional distress.
What the evidence shows
Anxiety and depression are common comorbidities in neurological disorders, negatively impacting quality of life and disease management. MBIs, which cultivate present-moment awareness and acceptance, have been evaluated across diverse neurological populations.
Burrowes et al. (2022) conducted a secondary analysis of a randomized clinical trial in episodic migraine patients, demonstrating that an enhanced mindfulness-based stress reduction program improved anxiety, depression, stress, and sleep quality compared to usual care. This supports MBIs’ potential to address overlapping neuropsychiatric symptoms in neurological conditions.
Kwok et al. (2025) reported that a multicomponent intervention including mindfulness significantly reduced distress among informal caregivers of people with dementia, highlighting MBIs’ utility in care partnerships affected by neurological disease.
Yang et al. (2026) found that mindfulness-based group therapy reduced auditory hallucinations and associated distress in schizophrenia, indicating applicability in severe neuropsychiatric manifestations.
Systematic reviews in related populations, such as perinatal women without pre-existing psychiatric disorders, confirm MBIs’ efficacy in reducing anxiety and depression symptoms (Corbally et al., 2021), suggesting generalizability of benefits.
Emerging mixed-methods research explores MBIs for stroke survivors and their care partners, showing promise in alleviating anxiety and depression post-stroke (unpublished mixed methods study, 2024).
Caveats and uncertainty
Heterogeneity in intervention protocols, duration, and outcome measures complicates synthesis of findings. Many studies have small sample sizes and short follow-up periods, limiting assessment of long-term effects.
The placebo effect and non-specific therapeutic factors may contribute to observed benefits. Blinding is challenging in behavioral interventions, increasing risk of bias.
Neurological disorders vary widely in symptomatology and severity, and MBIs may not be equally effective across all conditions or stages.
Further high-quality, adequately powered randomized controlled trials with standardized protocols are needed to confirm efficacy and identify optimal delivery modes.
How this may change practice
Clinicians should consider MBIs as complementary options for managing anxiety and depression in neurological patients, particularly when pharmacotherapy is contraindicated or insufficient.
Integration of MBIs into multidisciplinary care teams, including neuropsychology and rehabilitation services, may enhance holistic management.
Patient selection and tailoring of mindfulness programs to cognitive and functional capacities are important to maximize engagement and benefit.
Ongoing training and resource development will facilitate wider implementation of evidence-based MBIs in neurology settings.